Fuyuan Pharmaceuticals: Beimei Progesterone Topical Solution Obtains Approval Notice for Clinical Trials of Drugs

Sina Finance News on March 31, Fuyuan Pharmaceutical announced that its wholly-owned subsidiary Anhui Fuyuan has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the approved issuance of Bemei prostaglandin ointment. Bemei prostaglandin ointment promotes eyelash growth, making lashes longer, thicker, and darker, and is used to treat sparse eyelashes. Up to now, Anhui Fuyuan has invested approximately RMB 4,367,300 in research and development of Bemei prostaglandin ointment.